11 October 2021 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland has today published advice accepting three new medicines.

Olaparib (Lynparza) was accepted for the treatment of prostate cancer with a specific gene mutation and is the first targeted treatment for patients with this condition.

Read SMC press release